Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

This study has been completed.
Sponsor:
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015340
First received: April 18, 2001
Last updated: August 26, 2008
Last verified: August 2008

April 18, 2001
August 26, 2008
November 1997
Not Provided
  • Craving
  • Retention
  • Opioid withdrawal
  • Subjective rating
Same as current
Complete list of historical versions of study NCT00015340 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study

The purpose of this study is the safety and efficacy of Burprenorphine/Naloxone in the treatment of opioid dependence. A compassionate use study.

The objective of this study is to provide follow-up compassionate use treatment and evaluate long term safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment for subjects who have completed CS 1008 A and B.

Interventional
Phase 3
Masking: Open Label
Primary Purpose: Treatment
  • Heroin Dependence
  • Substance-Related Disorders
Drug: Buprenorphine/naloxone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
Not Provided
Not Provided

Inclusion Criteria:

completions of CS 1008 A/B

Exclusion Criteria:

Significant medical or psychiatric illness. Non-compliance with study procedures in CS 1008 A/B

Both
18 Years to 59 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00015340
NIDA-5-0013-14, Y01-5-0013-14
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
New York MDRU
Principal Investigator: Paul Casadonte, M.D. New York VAMC
National Institute on Drug Abuse (NIDA)
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP